170 related articles for article (PubMed ID: 27461140)
21. Optimization of performance of Dutch newborn screening for cystic fibrosis.
Bouva MJ; Dankert-Roelse JE; van der Ploeg C; Verschoof-Puite RK; Zomer-van Ommen DD; Gille J; Jakobs BS; Heijnen M; de Winter-de Groot KM
J Cyst Fibros; 2024 Jan; 23(1):120-125. PubMed ID: 37716879
[TBL] [Abstract][Full Text] [Related]
22. [Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol].
Sommerburg O; Stahl M; Hammermann J; Okun JG; Kulozik A; Hoffmann G; Mall M
Klin Padiatr; 2017 Mar; 229(2):59-66. PubMed ID: 28444650
[No Abstract] [Full Text] [Related]
23. Neonatal Screening for Cystic Fibrosis in Hungary-First-Year Experiences.
Xue A; Lénárt I; Kincs J; Szabó H; Párniczky A; Balogh I; Deák A; Monostori PB; Hegedűs K; Szabó AJ; Szatmári I
Int J Neonatal Screen; 2023 Aug; 9(3):. PubMed ID: 37754773
[TBL] [Abstract][Full Text] [Related]
24. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
25. Initial Evaluation of Prospective and Parallel Assessments of Cystic Fibrosis Newborn Screening Protocols in Eastern Andalusia: IRT/IRT versus IRT/PAP/IRT.
Sadik I; Pérez de Algaba I; Jiménez R; Benito C; Blasco-Alonso J; Caro P; Navas-López VM; Pérez-Frías J; Pérez E; Serrano J; Yahyaoui R
Int J Neonatal Screen; 2019 Sep; 5(3):32. PubMed ID: 33072991
[TBL] [Abstract][Full Text] [Related]
26. Immunoreactive trypsinogen in healthy newborns and infants with cystic fibrosis.
Fingerhut R; Rueegg CS; Imahorn O; Pedersen ESL; Kuehni CE; Gallati S; Regamey N; Barben J
Arch Dis Child Fetal Neonatal Ed; 2023 Mar; 108(2):176-181. PubMed ID: 36351789
[TBL] [Abstract][Full Text] [Related]
27. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
[TBL] [Abstract][Full Text] [Related]
28. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
[TBL] [Abstract][Full Text] [Related]
29. Improving outcomes for Colorado's IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs.
Martiniano SL; Croak K; Bonn G; Sontag MK; Sagel SD
Mol Genet Metab; 2021; 134(1-2):65-67. PubMed ID: 34489170
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
[TBL] [Abstract][Full Text] [Related]
31. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
Gregg RG; Simantel A; Farrell PM; Koscik R; Kosorok MR; Laxova A; Laessig R; Hoffman G; Hassemer D; Mischler EH; Splaingard M
Pediatrics; 1997 Jun; 99(6):819-24. PubMed ID: 9164776
[TBL] [Abstract][Full Text] [Related]
32. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
[TBL] [Abstract][Full Text] [Related]
33. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
34. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
35. Newborn screening for cystic fibrosis by use of a multiplex immunoassay.
Lindau-Shepard BA; Pass KA
Clin Chem; 2010 Mar; 56(3):445-50. PubMed ID: 20040620
[TBL] [Abstract][Full Text] [Related]
36. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening.
Korzeniewski SJ; Young WI; Hawkins HC; Cavanagh K; Nasr SZ; Langbo C; Teneyck KR; Grosse SD; Kleyn M; Grigorescu V
Pediatr Pulmonol; 2011 Feb; 46(2):125-30. PubMed ID: 20848586
[TBL] [Abstract][Full Text] [Related]
37. The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Roefs J; Gille JJ; Reijntjens S; Dompeling E; Dankert-Roelse JE
J Inherit Metab Dis; 2013 Jan; 36(1):147-54. PubMed ID: 22739940
[TBL] [Abstract][Full Text] [Related]
38. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
[TBL] [Abstract][Full Text] [Related]
39. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
[TBL] [Abstract][Full Text] [Related]
40. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
